Insufficient evidence of HPV Vaccine
Tuesday, March 17, 2009
Researchers argue that there is insufficient evidence for the effectiveness of the HPV vaccine.
There is not enough evidence to confidently be able to declare that the two popular vaccines against human papilloma virus (HPV) are reliable in preventing the development of cervical cancer, according to two articles in the New England Journal of Medicine.
"Despite great expectations and promising results from clinical trials, we have not yet sufficient evidence of an effective vaccine against cervical cancer," wrote Charlotte J. Haug, editor of The Journal of the Norwegian Medical Association, in the first article.
"With so many essential questions still unanswered, there is good reason to be cautious."
Haug noted that Merck Gardasil and Cervarix by Glaxo Smith Klein than six and half years have been clinically studied since 2006 on the market. This means that researchers still do not know whether the vaccine is effective against HPV in the longer term, or cancer-related side effects it will have.
For example, protecting the body against infection with certain HPV strains may have unexpected immunological side effects, the resistance of the body against other varieties greatly reduced.
Because of the novelty of both vaccines, it is not possible to see whether they reduce cervical cancer rates. Normally, it takes years of HPV infection before cancer can develop - more time than any of the "drug" has ever been studied.
In the second article, a few Harvard researchers noted that HPV vaccination does not necessarily cost-effective way to protect against cervical cancer.
The current research methods such as smears are very efficient in reducing the mortality of cervical cancer, but such tests should even after receiving an HPV vaccine continue.
Even in the best case, the vaccine does not protect against all cervical cancer strains can cause cancer and a woman is already a strain in the vaccine has been exposed will not benefit more from it.
"I believe that the vaccine is a major progress," said Philip Davies of the European Cervical Cancer Association, "but we have the right to examine the benefits, and that did not happen."
original source: Natural News